wap.stockstar1 小时
科伦药业：控股子公司抗PD-L1塔戈利单抗获批上市
（原标题：科伦药业：控股子公司抗PD-L1塔戈利单抗获批上市） 证券时报e公司讯，科伦药业(002422)1月1日晚间公告，公司控股子公司四川科伦博泰生物医药股份有限公司用于治疗既往接受过2线及以上化疗失败的复发或转移性鼻咽癌患者的靶向程序性细胞死亡配体1(PD-L1)的创新人源化单克隆抗体(简称“单抗”)塔戈利单抗(前称KL-A167)(科泰莱®)已获国家药监局批准于中国上市。
pharmaphorum2 天
Opdivo's subcutaneous PD-1 inhibitor cleared in US
Opdivo Qvantig (nivolumab and hyaluronidase) has been approved for use across almost all of Opdivo's lengthy list of ...
腾讯网7 天
“双管齐下”！中南大学周文虎教授团队：发现癌症治疗创新策略
【导读】黑色素瘤是一种恶性皮肤肿瘤，尤其是无法切除或已经转移的病例，治疗难度较大。12月24日，中南大学周文虎教授研究团队在期刊《Advanced Science》上发表了研究论文，题为“Co-Delivery of aPD-L1 and CD73 ...
2minutemedicine.com1 天
AstraZeneca’s Imfinzi shows positive results in phase 3 trial for treatment of limited ...
Imfinzi reduced risk of death by 27% and reduced disease progression by 24% compared to patients receiving a placebo. 2. In ...
Pharmaceutical Technology1 天
Enfortumab vedotin by Astellas Pharma for Solid Tumor: Likelihood of Approval
Enfortumab vedotin is under clinical development by Astellas Pharma and currently in Phase II for Solid Tumor.
pharmaphorum12 天
Ottimo raises $140m for its PD-1/VEGF cancer drug
Anglo-US biotech Ottimo Pharma has completed a big early-stage biotech financing, raising $140 million for its PD-1 and VEGF ...
Pharmaceutical Technology1 天
Envafolimab by Alphamab Oncology for Non-Small Cell Lung Cancer: Likelihood of Approval
Envafolimab is under clinical development by Alphamab Oncology and currently in Phase I for Non-Small Cell Lung Cancer.
Businessworld2 天
play microgaming slots
INR:0738. play microgaming slots R&D Daily: AstraZeneca's PD-L1 inhibitor receives priority review, reducing the number of treatments by half Phase 3 clini ...